Palvella Therapeutics (PVLA) Accumulated Expenses (2016 - 2024)
Historic Accumulated Expenses for Palvella Therapeutics (PVLA) over the last 12 years, with Q3 2024 value amounting to $3.5 million.
- Palvella Therapeutics' Accumulated Expenses fell 7294.74% to $3.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $3.5 million, marking a year-over-year decrease of 7294.74%. This contributed to the annual value of $1.4 million for FY2023, which is 8674.86% down from last year.
- Per Palvella Therapeutics' latest filing, its Accumulated Expenses stood at $3.5 million for Q3 2024, which was down 7294.74% from $5.4 million recorded in Q2 2024.
- Palvella Therapeutics' Accumulated Expenses' 5-year high stood at $19.7 million during Q3 2021, with a 5-year trough of $1.4 million in Q4 2023.
- In the last 5 years, Palvella Therapeutics' Accumulated Expenses had a median value of $9.1 million in 2023 and averaged $9.5 million.
- In the last 5 years, Palvella Therapeutics' Accumulated Expenses soared by 17066.64% in 2021 and then crashed by 8674.86% in 2023.
- Palvella Therapeutics' Accumulated Expenses (Quarter) stood at $7.7 million in 2020, then skyrocketed by 117.77% to $16.8 million in 2021, then crashed by 36.17% to $10.7 million in 2022, then tumbled by 86.75% to $1.4 million in 2023, then skyrocketed by 142.49% to $3.5 million in 2024.
- Its Accumulated Expenses stands at $3.5 million for Q3 2024, versus $5.4 million for Q2 2024 and $6.0 million for Q1 2024.